CLINICAL TRIALS PROFILE FOR DEXANABINOL
✉ Email this page to a colleague
Clinical Trials for Dexanabinol
| Trial ID | Title | Status | Sponsor | Phase | Summary |
|---|---|---|---|---|---|
| NCT00129857 ↗ | Dexanabinol in Severe Traumatic Brain Injury | Completed | Pharmos | Phase 3 | Each year a large number of patients are hospitalized at Shock Trauma Centers with severe head injuries. Bleeding into and swelling of these patients' brains may cause compression of vital structures, disability and death. Sometimes surgery is needed. Unfortunately, the investigators have no medication to treat the bad effects of head trauma. Part of the brain damage is due to toxic chemicals (including one called glutamate) that are released by the damaged nerves. Dexanabinol may prevent some of the bad effects of glutamate on the brain and may protect the brain against uncontrollable swelling and death. |
| NCT01489826 ↗ | A Phase 1 Study of Dexanabinol in Patients With Advanced Solid Tumours | Completed | e-Therapeutics PLC | Phase 1 | This study is a trial of Dexanabinol in patients with advanced solid tumours. The purposes of this protocol are to study different doses of the study drug to determine the maximum safe dose and to further understand the safety of the study drug; to understand what the body does to the study drug; to understand what the study drug does to the body and to measure any reduction in size of patients' cancer tumour(s). Dexanabinol is a synthetic cannabinoid derivative with reduced psychotropic potential which was initially investigated as a neuroprotective agent. Because of its method of action however it is thought that it may have the effect of destroying cancer cells by reducing the level of control on networks that prevent cancer cells dying. |
| NCT01654497 ↗ | Dexanabinol in Patients With Brain Cancer | Completed | e-Therapeutics PLC | Phase 1 | The purpose of this study is to try to determine the maximum safe dose of dexanabinol that can be administered to people with brain cancer. Other purposes of this study are to: - find out what effects (good and bad) dexanabinol has; - see how much drug gets into the body by collecting blood and cerebrospinal fluid for use in pharmacokinetic (PK) studies; - learn more about how dexanabinol might affect the growth of cancer cells; - look at biomarkers (biochemical features that can be used to measure the progress of disease or the effects of a drug). |
| NCT01654497 ↗ | Dexanabinol in Patients With Brain Cancer | Completed | Santosh Kesari, M.D., Ph.D. | Phase 1 | The purpose of this study is to try to determine the maximum safe dose of dexanabinol that can be administered to people with brain cancer. Other purposes of this study are to: - find out what effects (good and bad) dexanabinol has; - see how much drug gets into the body by collecting blood and cerebrospinal fluid for use in pharmacokinetic (PK) studies; - learn more about how dexanabinol might affect the growth of cancer cells; - look at biomarkers (biochemical features that can be used to measure the progress of disease or the effects of a drug). |
| NCT02054754 ↗ | Assessment of Single Doses of Oral Dexanabinol in Healthy Subjects | Completed | e-Therapeutics PLC | Phase 1 | The purpose of this study is to test the safety and observe the pharmacokinetics (distribution and elimination of the drug) of the compound dexanabinol (ETS2101) in healthy male subjects following a single oral dose. |
| NCT02423239 ↗ | A Study of Dexanabinol in Combination With Chemotherapy in Patients With Advanced Tumours | Unknown status | e-Therapeutics PLC | Phase 1 | This study is a trial of dexanabinol in patients with advanced tumours. The purposes of the protocol are to study different doses of the study drug to determine the maximum safe dose of the drug given in combination with standard chemotherapies and to further understand the safety of the study drug and to measure any reduction in size of patients' cancer tumour(s). Dexanabinol is a synthetic cannabinoid which has previously undergone clinical trials for traumatic brain injury (TBI) and in subjects undergoing coronary artery bypass surgery. Currently dexanabinol is under investigation for potential anti-tumour activity in patients with advanced tumours. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Summary |
Clinical Trial Conditions for Dexanabinol
Condition Name
Clinical Trial Locations for Dexanabinol
Trials by Country
Clinical Trial Progress for Dexanabinol
Clinical Trial Phase
Clinical Trial Sponsors for Dexanabinol
Sponsor Name
